Metformin in cancer: Translational challenges

Journal of Molecular Endocrinology

Volumn 48, Issue 3, 2012, Pages

  Dowling, Ryan J O ^a   Niraula, Saroj ^a   Stambolic, Vuk ^a   Goodwin, Pamela J ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; INSULIN RECEPTOR; METFORMIN; PLACEBO; STAT3 PROTEIN; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL POLYP; DISTANT METASTASIS FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; FATTY ACID OXIDATION; GLYCOLYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LIVER CANCER; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; MUSCLE CONTRACTION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY CANCER; OVERALL SURVIVAL; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; METFORMIN; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84861168776     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-12-0007     Document Type: Review

References (104)

1. Algire C, Zakikhani M, Blouin MJ, Shuai JH & Pollak M 2008 Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocrine-Related Cancer 15 833-839. (doi:10.1677/ERC-08-0038)
2. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE & Thor AD 2009 Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8 909-915. (doi:10.4161/cc.8.6.7933)
3. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M et al. 2005 Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Experimental Gerontology 40 685-693. (doi:10.1016/j.exger.2005.07.007)
4. Azoulay L, Dell'Aniello S, Gagnon B, Pollak M & Suissa S 2011 Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiology, Biomarkers & Prevention 20 337-344. (doi:10.1158/1055-9965.EPI-10-0940)
5. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C et al. 2004 The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biology & Therapy 3 772-775. (doi:10.4161/cbt.3.8.994)
6. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN & Gonzalez-Angulo AM 2012 Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118 1202-1211. (doi:10.1002/cncr.26439)
7. Belfiore A & Frasca F 2008 IGF and insulin receptor signaling in breast cancer. Journal of Mammary Gland Biology and Neoplasia 13 381-406. (doi:10.1007/s10911-008-9099-z)
8. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y & Bost F 2008 The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27 3576-3586. (doi:10.1038/sj.onc.1211024)
9. Berstein LM, Boyarkina MP, Tsyrlina EV, Turkevich EA & Semiglazov VF 2010a More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Medical Oncology 28 1260-1263. (doi:10.1007/s12032-010-9572-6)
10. Berstein LM, Yue W, Wang JP & Santen RJ 2010b Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Research and Treatment 128 109-117. (doi:10.1007/s10549-010-1072-z)
11. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E & Grassi G 2012 Cancer mortality reduction and metformin. A retrospective cohort study in type 2 diabetic patients. Diabetes, Obesity & Metabolism 14 23-29. (doi:10.1111/j.1463-1326.2011.01480.x)
12. Bodmer M, Meier C, Krahenbuhl S, Jick SS & Meier CR 2008 Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 31 2086-2091. (doi:10.2337/dc08-1171)
13. Bodmer M, Meier C, Krahenbuhl S, Jick SS & Meier CR 2010 Longterm metformin use is associated with decreased risk of breast cancer. Diabetes Care 33 1304-1308. (doi:10.2337/dc09-1791)
14. Bodmer M, Becker C, Meier C, Jick SS & Meier CR 2011 Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecological Oncology 123 200-204. (doi:10.1016/j.ygyno. 2011.06.038)
15. Bonanni B, Cazzaniga M, Puntoni M, Pruneri G, Serrano D, Lazzeroni M, Guerrieri-Gonzaga A, Macis D, Luini A, Veronesi A, et al. 2010 A randomized pre-surgical trial of metformin in breast cancer. Preliminary feasibility and safety results. San Antonio Breast Cancer Symposium, (PD03-02).
16. Bosco JL, Antonsen S, Sorensen HT, Pedersen L & Lash TL 2011 Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiology, Biomarkers & Prevention 20 101-111. (doi:10.1158/1055-9965.EPI-10-0817)
17. Bowker SL, Majumdar SR, Veugelers P & Johnson JA 2006 Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29 254-258. (doi:10.2337/diacare.29.02.06.dc05-1558)
18. Brown KA, Hunger NI, Docanto M & Simpson ER 2010 Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Research and Treatment 123 591-596. (doi:10.1007/s10549-010-0834-y)
19. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W et al. 2004 Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53 1052-1059. (doi:10.2337/diabetes.53.4.1052)
20. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B & Thompson CB 2007 Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Research 67 6745-6752. (doi:10.1158/0008-5472.CAN-06-4447)
21. Calle EE, Rodriguez C, Walker-Thurmond K & Thun MJ 2003 Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine 348 1625-1638. (doi:10.1056/NEJMoa021423)
22. Campbell LL & Polyak K 2007 Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6 2332-2338. (doi:10.4161/cc.6.19.4914)
23. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA & Bae-Jump VL 2010 Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy. Gynecological Oncology 116 92-98. (doi:10.1016/j.ygyno.2009.09.024)
24. Currie CJ, Poole CD & Gale EA 2009 The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 52 1766-1777. (doi:10.1007/s00125-009-1440-6)
25. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B & Gandini S 2010 Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Research 3 1451-1461. (doi:10.1158/1940-6207.CAPR-10-0157)
26. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R & Thor AD 2012 Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 11 367-376. (doi:10.4161/cc.11.2.18813)
27. Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G et al. 2009 Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World Journal of Gastroenterology 15 2506-2511. (doi:10.3748/wjg.15.2506)
28. Dowling RJ, Zakikhani M, Fantus IG, Pollak M & Sonenberg N 2007 Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research 67 10804-10812. (doi:10.1158/0008-5472.CAN-07-2310)
29. Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R & McTiernan A 2011 Associations of insulin resistance and adiponectin with mortality in women with breast cancer. Journal of Clinical Oncology 29 32-39. (doi:10.1200/JCO.2009.26.4473)
30. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M & Leverve X 2000 Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. Journal of Biological Chemistry 275 223-228. (doi:10.1074/jbc.275.1.223)
31. Emaus A, Veierod MB, Tretli S, Finstad SE, Selmer R, Furberg AS, Bernstein L, Schlichting E & Thune I 2010 Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Research and Treatment 121 651-660. (doi:10.1007/s10549-009-0603-y)
32. Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, Laughlin GA, Saquib N, Rock CL & Pierce JP 2011 Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. Journal of Clinical Oncology 29 54-60. (doi:10.1200/JCO. 2010.29.3183)
33. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR & Morris AD 2005 Metformin and reduced risk of cancer in diabetic patients. BMJ 330 1304-1305. (doi:10.1136/bmj.38415.708634.F7)
34. Everhart J & Wright D 1995 Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. Journal of the American Medical Association 273 1605-1609. (doi:10.1001/jama.1995.03520440059037)
35. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F & Viollet B 2010 Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. Journal of Clinical Investigation 120 2355-2369. (doi:10.1172/JCI40671)
36. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B & Hood N 2002 Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. Journal of Clinical Oncology 20 42-51. (doi:10.1200/JCO.20.1.42)
37. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M & Fantus IG 2008 Insulin-lowering effects of metformin in women with early breast cancer. Clinical Breast Cancer 8 501-505. (doi:10.3816/CBC.2008.n.060)
38. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA et al. 2011 Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment 126 215-220. (doi:10.1007/s10549-010-1224-1)
39. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE & Shaw RJ 2008 AMPK phosphorylation of raptor mediates a metabolic checkpoint. Molecular Cell 30 214-226. (doi:10.1016/j.molcel.2008.03.003)
40. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L et al. 2011 Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Research and Treatment 128 783-794. (doi:10.1007/s10549-011-1612-1)
41. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL et al. 2010 Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116 1938-1946. (doi:10.1002/cncr.24982)
42. Hawley SA, Gadalla AE, Olsen GS & Hardie DG 2002 The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51 2420-2425. (doi:10.2337/diabetes.51.8.2420)
43. Hirsch HA, Iliopoulos D, Tsichlis PN & Struhl K 2009 Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Research 69 7507-7511. (doi:10.1158/0008-5472.CAN-09-2994)
44. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K et al. 2010 Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prevention Research 3 1077-1083. (doi:10.1158/1940- 6207.CAPR-10-0186)
45. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S & Alessi DR 2008 Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTENdeficient mice. Biochemical Journal 412 211-221. (doi:10.1042/BJ20080557)
46. Iliopoulos D, Hirsch HA & Struhl K 2011 Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Research 71 3196-3201. (doi:10.1158/0008-5472.CAN-10-3471)
47. Inoki K, Li Y, Xu T & Guan KL 2003 Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes and Development 17 1829-1834. (doi:10.1101/gad.1110003)
48. Irwin ML, Duggan C, Wang CY, Smith AW, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L & Ballard-Barbash R 2011 Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. Journal of Clinical Oncology 29 47-53. (doi:10.1200/JCO.2010.28.4752)
49. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, Micic D & Trajkovic V 2007 Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cellular and Molecular Life Sciences 64 1290-1302. (doi:10.1007/s00018-007-7080-4)
50. Jin HE, Hong SS, Choi MK, Maeng HJ, Kim DD, Chung SJ & Shim CK 2009 Reduced antidiabetic effect of metformin and downregulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis. Pharmaceutical Research 26 549-559. (doi:10.1007/s11095-008-9770-5)
51. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN & Gonzalez-Angulo AM 2009 Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. Journal of Clinical Oncology 27 3297-3302. (doi:10.1200/JCO.2009. 19.6410)
52. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ & Thompson CB 2005 AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Molecular Cell 18 283-293. (doi:10.1016/j.molcel.2005.03.027)
53. Kahn BB, Alquier T, Carling D & Hardie DG 2005 AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 1 15-25. (doi:10.1016/j.cmet.2004.12.003)
54. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ et al. 2010 Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPasedependent manner. Cell Metabolism 11 390-401. (doi:10.1016/j.cmet.2010.03.014)
55. Kasper JS & Giovannucci E 2006 A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 15 2056-2062. (doi:10.1158/1055-9965.EPI-06-0410)
56. Kasper JS, Liu Y & Giovannucci E 2009 Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. International Journal of Cancer 124 1398-1403. (doi:10.1002/ijc.24044)
57. Kendall DM & Bergenstal RM 2001 Comprehensive management of patients with type 2 diabetes: establishing priorities of care. American Journal of Managed Care 7 S327-S343 (quiz S344-328).
58. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO & Bilo HJ 2010 Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33 322-326. (doi:10.2337/dc09-1380)
59. Larsson SC & Wolk A 2011 Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 54 1013-1018. (doi:10.1007/s00125-011-2051-6)
60. Larsson SC, Orsini N & Wolk A 2005 Diabetes mellitus and risk of colorectal cancer: a meta-analysis. Journal of the National Cancer Institute 97 1679-1687. (doi:10.1093/jnci/dji375)
61. Larsson SC, Orsini N, Brismar K & Wolk A 2006 Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49 2819-2823. (doi:10.1007/s00125-006-0468-0)
62. Larsson SC, Mantzoros CS & Wolk A 2007 Diabetes mellitus and risk of breast cancer: a meta-analysis. International Journal of Cancer 121 856-862. (doi:10.1002/ijc.22717)
63. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ & Lee SH 2005 PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24 1477-1480. (doi:10.1038/sj.onc.1208304)
64. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH & Huang YC 2011 Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800 000 individuals. BMC Cancer 11 20. (doi:10.1186/1471-2407-11-20)
65. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH & Kim WH 2012 The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. International Journal of Cancer. In press. (doi:10.1002/ijc.26421)
66. Li D, Yeung SC, Hassan MM, Konopleva M & Abbruzzese JL 2009 Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137 482-488. (doi:10.1053/j.gastro.2009.04.013)
67. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD & Evans JM 2009 New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32 1620-1625. (doi:10.2337/dc08-2175)
68. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, Oshima RG & Abraham RT 2005 Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Research 65 5325-5336. (doi:10.1158/0008-5472. CAN-04-4589)
69. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE & Thor AD 2009 Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8 2031-2040. (doi:10.4161/cc.8.13.8814)
70. Liu B, Fan Z, Edgerton SM, Yang X, Lind SE & Thor AD 2011 Potent anti-proliferative effects of metformin on trastuzumabresistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle 10 2959-2966. (doi:10.4161/cc.10.17.16359)
71. Long YC & Zierath JR 2006 AMP-activated protein kinase signaling in metabolic regulation. Journal of Clinical Investigation 116 1776-1783. (doi:10.1172/JCI29044)
72. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M & Stampfer MJ 2008 Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncology 9 1039-1047. (doi:10.1016/S1470-2045 (08)70235-3)
73. Mazzone PJ, Rai HS, Beukemann M, Xu M, Abdallah R & Sasidhar M 2010 The effect of metformin and thiazolidinedione use on lung cancer. Chest 138 (Suppl 882A).
74. Meiers P, Sharon E, Dong Yu W, Pooni A, McCready D & Leong W 2010 Significant reduction of triple negative breast cancers in diabetic women onmetformin. San Antonio Breast Cancer Symposium, (PD03-01).
75. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD & Dennis PA 2010 Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prevention Research 3 1066-1076. (doi:10.1158/1940-6207.CAPR-10-0055)
76. Mitri J, Castillo J & Pittas AG 2008 Diabetes and risk of non-Hodgkin's lymphoma: a meta-analysis of observational studies. Diabetes Care 31 2391-2397. (doi:10.2337/dc08-1034)
77. Monami M, Lamanna C, Balzi D, Marchionni N & Mannucci E 2009 Sulphonylureas and cancer: a case-control study. Acta Diabetologica 46 279-284. (doi:10.1007/s00592-008-0083-2)
78. Monami M, Colombi C, Balzi D, Dicembrini I, Giannini S, Melani C, Vitale V, Romano D, Barchielli A, Marchionni N et al. 2011 Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 34 129-131. (doi:10.2337/dc10-1287)
79. Morgensztern D & McLeod HL 2005 PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-Cancer Drugs 16 797-803. (doi:10.1097/01.cad.0000173476.67239.3b)
80. Mulligan AM, O'Malley FP, Ennis M, Fantus IG & Goodwin PJ 2007 Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Research and Treatment 106 39-47. (doi:10.1007/s10549-006-9471-x)
81. Niraula S, Stambolic V, Dowling RJO, Ennis M, Chang MC, Done SJ, Hallak S, Hood N, Leong W, Escallon J, et al. 2010 Clinical and biologic effects of metformin in early stage breast cancer. San Antonio Breast Cancer Symposium, (PD03-06).
82. Papa V & Belfiore A 1996 Insulin receptors in breast cancer: biological and clinical role. Journal of Endocrinological Investigation 19 324-333.
83. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A & Panico S 2006 Metabolic syndrome as a prognostic factor for breast cancer recurrences. International Journal of Cancer 119 236-238. (doi:10.1002/ijc.21812)
84. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L & Stal O 2007 PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clinical Cancer Research 13 3577-3584. (doi:10.1158/1078-0432.CCR-06-1609)
85. Phoenix KN, Vumbaca F & Claffey KP 2009 Therapeutic metformin/ AMPK activation promotes the angiogenic phenotype in the Era negative MDA-MB-435 breast cancer model. Breast Cancer Research and Treatment 113 101-111. (doi:10.1007/s10549-008-9916-5)
86. Phoenix KN, Vumbaca F, Fox MM, Evans R & Claffey KP 2010 Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Research and Treatment 123 333-344. (doi:10.1007/s10549-009-0647-z)
87. Pisani P 2008 Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Archives of Physiology and Biochemistry 114 63-70. (doi:10.1080/13813450801954451)
88. Pollak M 2008 Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews. Cancer 8 915-928. (doi:10.1038/nrc2536)
89. Polyak K & Weinberg RA 2009 Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews. Cancer 9 265-273. (doi:10.1038/nrc2620)
90. Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B et al. 2011 Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausalwomen:NCICCTGMA.14. Journal of ClinicalOncology 29 3869-3876. (doi:10.1200/JCO.2010.33.7006)
91. Sansal I & Sellers WR 2004 The biology and clinical relevance of the PTEN tumor suppressor pathway. Journal of Clinical Oncology 22 2954-2963. (doi:10.1200/JCO.2004.02.141)
92. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, De Pinho RA & Cantley LC 2004 The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6 91-99. (doi:10.1016/j.ccr.2004.06.007)
93. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M & Cantley LC 2005 The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 1642-1646. (doi:10.1126/science.1120781)
94. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG et al. 2007 Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. Journal of Clinical Investigation 117 1422-1431. (doi:10.1172/JCI30558)
95. Stambolic V, Woodgett JR, Fantus IG, Pritchard KI & Goodwin PJ 2009 Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Research and Treatment 114 387-389. (doi:10.1007/s10549-008-0015-4)
96. Tan BX, Yao WX, Ge J, Peng XC, Du XB, Zhang R, Yao B, Xie K, Li LH, Dong H et al. 2011 Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 117 5103-5111. (doi:10.1002/cncr. 26151)
97. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, Nakajima N, Nagashima Y, Wada K, Nakagama H et al. 2008 Metformin suppresses intestinal polyp growth in ApcMin/C mice. Cancer Science 99 2136-2141. (doi:10.1111/j.1349-7006.2008.00933.x)
98. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolic I, Koepsell H & Brockmoller J 2009 The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clinical Pharmacology and Therapeutics 86 299-306. (doi:10.1038/clpt.2009.92)
99. Vazquez-Martin A, Oliveras-Ferraros C & Menendez JA 2009 The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8 88-96. (doi:10.4161/cc.8. 1.7499)
100. Wright JL & Stanford JL 2009 Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes & Control 20 1617-1622. (doi:10.1007/s10552-009-9407-y)
101. Yu D & Hung MC 2000 Overexpression of ErbB2 in cancer and ErbB2- targeting strategies. Oncogene 19 6115-6121. (doi:10.1038/sj.onc. 1203972)
102. Zakikhani M, Dowling R, Fantus IG, Sonenberg N & Pollak M 2006 Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research 66 10269-10273. (doi:10.1158/0008-5472.CAN-06-1500)
103. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D & Yu D 2004 Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clinical Cancer Research 10 6779-6788. (doi:10.1158/1078-0432.CCR-04-0112)
104. Zhuang Y & Miskimins WK 2008 Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. Journal of Molecular Signaling 3 18. (doi:10.1186/1750-2187-3-18)